About pcm
Manuscript Submission
AME Editing Service
Reprint & Permission
Advertising
Contact us
-
General editorial enquiries:
Email: pcm@amegroups.com -
Copyright related contact:
Email: permissions@amegroups.com -
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com
PCM Chinese Edition more
早期三阴性乳腺癌免疫检查点抑制剂回顾
三阴性乳腺癌(triple negative breast... More >>人类肿瘤中BRAF改变的叙述性综述:诊断和预测意义
B-Raf原癌基因,丝氨酸/苏氨酸激酶( BRAF... More >>营养影响疾病的潜在分子机制
人体约有50至70万亿个细胞,每个细胞都在高度复杂的生物系统网络中发挥... More >>
Case Report
Precision Cancer Medicine
2023;
6:
10
(30 March 2023)
Case Report
Precision Cancer Medicine
2023;
6:
9
(30 March 2023)
Review Article
Precision Cancer Medicine
2023;
6:
8
(30 March 2023)
Review Article
Precision Cancer Medicine
2023;
6:
7
(30 March 2023)
Review Article
Precision Cancer Medicine
2023;
6:
6
(30 March 2023)
Review Article
Precision Cancer Medicine
2023;
6:
5
(30 March 2023)
Review Article
Precision Cancer Medicine
2023;
6:
4
(30 March 2023)
Original Article
Precision Cancer Medicine
2023;
6:
3
(30 March 2023)
Editorial
Precision Cancer Medicine
2023;
6:
2
(30 March 2023)
Editorial
Precision Cancer Medicine
2023;
6:
1
(30 March 2023)
Case Report
Precision Cancer Medicine
2022;
5:
40
(30 December 2022)
Review Article
Precision Cancer Medicine
2022;
5:
39
(30 December 2022)
Review Article
Precision Cancer Medicine
2022;
5:
38
(30 December 2022)
Review Article
Precision Cancer Medicine
2022;
5:
37
(30 December 2022)
Study Protocol
Precision Cancer Medicine
2022;
5:
36
(30 December 2022)
Original Article
Precision Cancer Medicine
2022;
5:
35
(30 December 2022)
Original Article
Precision Cancer Medicine
2022;
5:
34
(30 December 2022)
Expert Consensus
Precision Cancer Medicine
2022;
5:
33
(30 December 2022)
Editorial
Precision Cancer Medicine
2022;
5:
32
(30 December 2022)
Editorial
Precision Cancer Medicine
2022;
5:
31
(30 December 2022)
Case Report
Case Report: Precision Oncology Tumor Board